These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

733 related items for PubMed ID: 27569674

  • 1. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
    Reilly PA, van Ryn J, Grottke O, Glund S, Stangier J.
    Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
    [Abstract] [Full Text] [Related]

  • 2. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.
    Reilly PA, van Ryn J, Grottke O, Glund S, Stangier J.
    Am J Emerg Med; 2016 Nov; 34(11S):26-32. PubMed ID: 27707528
    [Abstract] [Full Text] [Related]

  • 3. Evidence Supporting Idarucizumab for the Reversal of Dabigatran.
    Pollack CV.
    Am J Med; 2016 Nov; 129(11S):S73-S79. PubMed ID: 27568285
    [Abstract] [Full Text] [Related]

  • 4. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
    Sié P.
    Drug Des Devel Ther; 2016 Nov; 10():1683-9. PubMed ID: 27274201
    [Abstract] [Full Text] [Related]

  • 5. Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases.
    Vosko MR, Bocksrucker C, Drwiła R, Dulíček P, Hauer T, Mutzenbach J, Schlimp CJ, Špinler D, Wolf T, Zugwitz D.
    J Thromb Thrombolysis; 2017 Apr; 43(3):306-317. PubMed ID: 28210988
    [Abstract] [Full Text] [Related]

  • 6. Idarucizumab: First Global Approval.
    Burness CB.
    Drugs; 2015 Dec; 75(18):2155-61. PubMed ID: 26578027
    [Abstract] [Full Text] [Related]

  • 7. Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review.
    Thibault N, Morrill AM, Willett KC.
    Am J Ther; 2018 Dec; 25(3):e333-e338. PubMed ID: 27175894
    [Abstract] [Full Text] [Related]

  • 8. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
    Tummala R, Kavtaradze A, Gupta A, Ghosh RK.
    Int J Cardiol; 2016 Jul 01; 214():292-8. PubMed ID: 27082776
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Reversing the anticoagulation effects of dabigatran.
    Dager WE, Banares L.
    Hosp Pract (1995); 2017 Apr 01; 45(2):29-38. PubMed ID: 28335637
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols.
    Huisman MV, Fanikos J.
    Am J Med; 2016 Nov 01; 129(11S):S89-S96. PubMed ID: 27569673
    [Abstract] [Full Text] [Related]

  • 16. Idarucizumab: The Antidote for Reversal of Dabigatran.
    Eikelboom JW, Quinlan DJ, van Ryn J, Weitz JI.
    Circulation; 2015 Dec 22; 132(25):2412-22. PubMed ID: 26700008
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. idarucizumab (PRAXBIND°). Don't rely too heavily on this dabigatran antidote.
    Prescrire Int; 2016 Nov 22; 25(176):260-263. PubMed ID: 30715821
    [Abstract] [Full Text] [Related]

  • 19. Evidence supporting idarucizumab for the reversal of dabigatran.
    Pollack CV.
    Am J Emerg Med; 2016 Nov 22; 34(11S):33-38. PubMed ID: 27697436
    [Abstract] [Full Text] [Related]

  • 20. [The first use of iv. idarucizumab for dabigatran reversal in Hungary].
    Driesz L, Barabás É, Bodócs I, Szántó Z, Herr G, Bencsik G, Pál L, Borbola J.
    Orv Hetil; 2017 Mar 22; 158(10):387-392. PubMed ID: 28270004
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.